FDA Pharmacy Compounding Advisory Committee to hold a meetingThe Committee discusses proposed criteria for developing the list of bulk drug substances that may be used to compound drug products in accordance with section 503A of the FD&C Act and also discusses six substances nominated for inclusion on the list on Day 2 of the meeting being held at FDA Silver Spring, MD's offices on February 24 at 8:15 am. Webcast Link

07:42 EDT

FDA to hold a joint advisory committee meetingThe Dermatologic & Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel discuss Avedro's New Drug Application (NDA) 203324 for Riboflavin Ophthalmic Solutions with UV-A irradiation which are used in corneal collagen cross-linking and proposed to be indicated for treatment of progressive keratoconus or corneal ectasia following refractive surgery in a joint committee meeting being held in FDA Silver Spring, Maryland's offices on February 24 at 8 am. Webcast Link